Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Status:
RECRUITING
Trial end date:
2030-12-23
Target enrollment:
Participant gender:
Summary
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.